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Abstract 
The successful use of tumor-draining lymph nodes (TDLN) as a source of effector cells for 
cancer immunotherapy depends largely on the immunogenicity of the tumor drained by the 
lymph nodes as well as the methods for secondary in vitro T cell activation and expansion. 
We transferred the bacterial superantigen staphylococcal enterotoxin A (SEA) gene into 
B16 murine melanoma tumor cells, and used them to induce TDLN (SEA TDLN) in synge-
neic hosts. Wild-type (wt) TDLN induced by parental B16 tumor was used as a control. In 
vitro, SEA TDLN cells proliferated more vigorously, produced more IFNγ and demonstrated 
higher CTL activity than wt TDLN cells when activated with anti-CD3/anti-CD28/IL-2. In 
vivo, SEA TDLN cells mediated tumor eradication more effectively than similarly activated wt 
TDLN cells (p<0.01). Furthermore, use of dendritic cells (DC) plus tumor antigen in vitro in 
addition to anti-CD3/anti-CD28/IL-2 stimulation further amplified the immune function and 
therapeutic efficacy of SEA TDLN cells. DC-stimulated SEA TDLN cells eliminated nearly 
90% of the pulmonary metastasis in mice bearing established B16 melanoma micrometasta-
ses. These results indicate that enforced expression of superantigen SEA in poorly immu-
nogenic tumor cells can enhance their immunogenicity as a vaccine in vivo. The combined use 
of genetically modified tumor cells as vaccine to induce TDLN followed by secondary 
stimulation using antigen-presenting cells and tumor antigen in a sequential immuniza-
tion/activation procedure may represent a unique method to generate more potent effector 
T cells for adoptive immunotherapy of cancer. 
Key words: Staphylococcal enterotoxin A (SEA), B16 melanoma, dendritic cells (DC), T lympho-
cyte, Adoptive therapy 
Introduction 
Adoptive T cell therapy has been used with 
success for the treatment of malignant diseases [1-4]. 
In addition to peripheral blood and tumor-infiltrating 
lymphocytes (TIL) [1-2], tumor-draining lymph nodes 
(TDLN) have been used successfully to provide 
“pre-effectors” for the generation of antitumor “ef-Int. J. Biol. Sci. 2009, 5 
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fector” T cells for adoptive transfer [3-8]. Tumor cells 
are typically poorly immunogenic. The same mecha-
nisms that developed to avoid the induction of im-
mune responses against self tissues, e.g. autoimmu-
nity, have to be overcome during the immunotherapy 
of cancer. Since the majority of malignancies arise in 
immunocompetent hosts, it is suggested that tumor 
cells escape normal host surveillance and defenses. 
Therefore, appropriate immune modification and 
stimulation may grant therapeutic benefits.   
  To modulate tumor immunogenicity, multiple 
strategies have been attempted. Genetic modification 
by introducing genes encoding immunomodulating 
molecules into tumor cells represents one approach. 
To this end, retroviruses encoding MHC II molecules 
were introduced directly into mammary carcinoma 
and ocular melanoma cells to facilitate the presenta-
tion of MHC class II-restricted tumor peptides to CD4 
T cells for tumor rejection [9]. Genetically modified 
tumors expressing costimulatory molecule CD40L 
elicited profoundly expanded tumor immune re-
sponses [10-11]. B7-dependent costimulatory signals 
play a central role in T cell activation. It has been 
proposed that the lack of immunogenicity of many 
tumor types could be due to the lack of B7 expression. 
Indeed, it was proved that transfection of B7 genes 
greatly augmented the immunogenicity of EL-4 lym-
phoma cells [12], leukemia cells [10], and sarcoma 
cells by inducing significant T cell activation, prolif-
eration and production of Th1 cytokines, e.g. IL-2 and 
IFNγ [13]. Moreover, C26 carcinoma cells transduced 
with OX40 ligand (OX40L) together with GM-CSF, 
which is known to activate antigen-presenting cells 
(APC), mounted a superior antitumor response by 
interacting directly with both APC and T cells in vivo 
[14]. It was likewise reported that vaccination with rat 
9L gliosarcoma cells expressing IL-4 induced specific 
protective immune response against challenge with 
parental 9L tumors by promoting both cellular and 
humoral responses [15]. In addition to mono- or 
bi-gene transfer, combinatorial costimulator protein 
transfer onto tumor cell surfaces was also evaluated 
for the induction of tumor immunogenicity. In highly 
aggressive L5178Y-R lymphomas, for example, a 
"tetra-costimulator" combination of B7-1, 4-1BBL, 
CD48, and CD40L induced complete tumor regres-
sion in 45% of treated mice and systemic antitumor 
immunity [16]. Overall, these achievements have 
made gene modification an attractive approach to 
enhance tumor immunogenicity. In addition, the role 
of BCG as an adjuvant in autologous tumor vaccines 
has been examined [17]. In patients with renal cell 
cancer, we inoculated irradiated tumor cells alone 
(wild-type, WT) or tumor cells with BCG intrader-
mally into contralateral thighs to induce draining 
vaccine-primed lymph nodes (WT-VPLN and 
BCG-VPLN). BCG increased the number of harvested 
VPLN cells by 10-fold. BCG-VPLN had significantly 
greater percentages of CD3
+ and CD4
+ T cells com-
pared to WT-VPLN. Anti-CD3/CD28-activated 
BCG-VPLN cells were found to have a greater release 
of IFNγ compared with WT-VPLN cells. Collectively, 
these data demonstrated the immunological effects of 
BCG and thus support its use as an adjuvant in 
autologous tumor vaccines.  
Bacterial superantigen staphylococcal entero-
toxin A (SEA) is an extremely potent activator of T 
lymphocytes when presented on MHC II molecules. 
SEA and SEB interact directly with the anti-
gen-binding groove of MHCⅡ molecules and ligate 
T cell receptor on its Vβ region without the need of 
APC or antigen processing [18]. This leads to power-
ful activation of T cells, determined by TCR Vβ rep-
ertoire and MHC haplotype [19]. In one study, a tu-
mor cell vaccine modified with transmem-
brane-anchored SEA (TM-SEA) using a protein 
transfer technique provoked a strong antitumor effect 
both in vitro and in vivo [20]. An alternative approach 
used SEA conjugated to tumor-specific mAb to de-
liver SEA to specific antigen-expressing tumor cells. 
The surface-bound SEA directed T cells to lyse the 
tumor cells in the absence of MHC II via low affinity 
TCR-SEA interaction [21]. These reports thus raised 
the prospect that genetic modification of tumor cells 
with the SEA gene may lead to the development of a 
novel therapeutic strategy to increase tumor immu-
nogenicity.  
 Dendritic cells (DC) have been used in vivo ei-
ther as a vaccine to induce antitumor pre-effector T 
cells in vaccine-primed lymph nodes (VPLN) or to 
boost adoptively transferred T cells. We have used 
un-pulsed DC in a couple of previous studies [22, 23]. 
DCs were injected intratumorally (i.t). In this way, the 
un-pulsed DC will present tumor antigen obtained 
from the tumor, which was proven to be the case in 
our subsequent studies [24]. We also reported that 
administration of DC pulsed with tumor lysate re-
sulted in an approximately eightfold hypertrophy of 
the VPLN, with an increased influx of DC and B cells 
in the lymph nodes. The adoptive transfer of 
DC-induced VPLN cells secondarily activated with 
anti-CD3/IL-2 resulted in regression of established 
3-day pulmonary metastases [25]. When tu-
mor-bearing mice were treated with cultured T cells, 
concurrent vaccination using peptide-pulsed DC 
during adoptive T cell transfer led to a more robust 
antitumor response than the use of each treatment Int. J. Biol. Sci. 2009, 5 
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individually [26]. DC-mediated potent antitumor 
immune responses in vivo correlated with 
DC-modulated vigorous antitumor immunity in vitro 
[27]. This led to the prediction that DC may function 
as a powerful stimulator during T cell culture in vitro 
to generate effector cells for adoptive transfer. We 
have used polyclonal T cell specific antibodies 
anti-CD3, anti-CD28 and T cell growth factor IL-2 to 
generate tumor-reactive T cells for cancer adoptive 
immunotherapy [7-8, 28-30]. We postulated that use 
of anti-CD3/anti-CD28/IL-2 in concert with DC plus 
tumor antigen in culture might generate large num-
bers of effector T cells from TDLN with augmented 
antitumor reactivity.   
The murine B16 melanoma cell line is poorly 
immunogenic and highly aggressive. In this study, 
we transfected SEA gene into B16 melanoma tumor 
cells by means of liposome-mediated transfection. We 
explored whether this strategy would increase the 
immunogenicity of the B16 tumor by examining the 
induction of tumor-reactive T cells within the lymph 
nodes draining the genetically modified tumor. Fur-
thermore, we examined the potential of using DC and 
tumor antigen in addition to 
anti-CD3/anti-CD28/IL-2  in vitro to generate more 
potent antitumor effector T cells from these lymph 
node cells previously sensitized in vivo by the 
SEA-expressing B16 tumor vaccine. 
Materials and methods   
1. The construction of recombinant pcDNA3.1 
(+)/SEA  
The SEA gene was amplified by PCR using the 
plasmid pGEM-Teasy-SEA as a template. The se-
quence was amplified with sense (F1; 
5'-CTCAGCTAGCCACCATGAAAAAAACAGCATT
TACATTA-3') and antisense (R1; 
5'-CCGGAATTCACTTGTATATAAATAT-3') prim-
ers. The PCR product was digested with Nhe I and 
EcoR I and ligated with similarly digested pcDNA3.1 
(+). The recombinant pcDNA3.1 (+)/SEA was ana-
lyzed by restriction enzyme digestion and the correct 
plamids were identified by DNA sequencing. 
2. Cell lines and transfections  
B16 tumor cells were maintained in Dulbecco’s 
Modified Eagle’s Medium (DMEM) supplemented 
with 15% fetal bovine serum, 100U of penicillin and 
100  μg of streptomycin/ml. Cells were transfected 
with 10 μg of plasmid by Lipofectamine 2000 follow-
ing the manufacturer’s instructions (Invitrogen, 
Carlsbad, CA). The stably transfected B16 cells were 
seeded into selection medium containing 400 μg/ml 
of G418 to obtain G418-resistant clones. The 
G418-resistant clones were then maintained in G418 
at a concentration of 200 μg/ml. Total RNA was iso-
lated and cDNA was synthesized by AMV reverse 
transcriptase (Promega, Madison, WI). SEA gene was 
amplified by PCR with F1 and R1. The products were 
then identified by DNA agarose gel electrophoresis. 
3. Animals and tumors 
B16 melanoma was from Cell Centre of Shang-
hai, China. The syngeneic mice, C57BL/6 (B6) mice, 
female, were purchased from the Animal Center of 
Academy of Military Medical Sciences (Beijing, 
China) and were used at 8 weeks or older.   
4. Generation of DC 
Mice were injected via tail vein with cyclophos-
phamide at 200 mg/kg to induce splenomegaly. Eight 
days later, spleens were harvested. Splenocyte sus-
pension was prepared and depleted of erythrocytes. 
The resultant cells were suspended at 1×106 /ml in 
complete medium (CM). One liter CM is composed of 
1, 000 ml RPMI 1640 medium (Gibco, Grand Tsland, 
NY) supplemented with 10% fetal calf serum (FCS), 
2.60g Hepes (Huamei, , Beijing, China), 2g NaHCO3 
and penicillin/streptomycin (Sigma, St.Louis, MO) at 
a final concentration of 100U/mL. Cells were cul-
tured in flask at 37o with 5% CO2. Three days later, 
culture medium and the non-adherent cells were re-
moved and discarded. Adherent cells were then cul-
tured with fresh CM containing GM-CSF and IL-4. 
Recombinant mouse (rm) GM-CSF (20 ng/ml Gibco) 
and rmIL-4 (10 ng/ml Gibco) were added to CM for 
DC culture. Half of the culture medium was replaced 
with fresh medium every 2 days. Five days later, 
TNFα (1 ng/ml) was added. After culture for 2 more 
days, cells were collected for morphological observa-
tion under microscopes, and DC phenotype profile 
was confirmed by FACS staining.   
5. Morphological observation of DCs  
Phase-contrast microscope (Carl Zeiss, Oberko-
chen, Germany) was used for DC morphological ob-
servation. For use of scanning electron microscopy, 
cultured DC cells were put on glass cover slips. The 
slips were washed with PBS and then fixed in 4% 
precooled glutaraldehyde for 2 hour at 4oC. After 
washing 2 times with PBS, the cells were fixed again 
in 1% osmic acid for 1 hour at 4oC. Cells were washed 
with PBS twice followed by dehydration through a 
graded series of ethanol and were dried at CO2 criti-
cal-point. Specimens were then observed in a scan-
ning electron microscope S-4500 (Hitachi, Ibaraki, 
Japan) at an accelerating voltage of 3kV. For use of 
transmission electron microscopy, fixed cells were 
embedded in Epon-812. Thin sections were then cut, Int. J. Biol. Sci. 2009, 5 
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stained with uracyl acetate and lead nitrate, and then 
examined in a transmission electron microscope 
TEM-600 (Hitachi, Ibaraki, Japan) at an accelerating 
voltage of 50kV.   
6.Phenotype analysis of DC and intracellular 
staining of cytokines secreted by stimulated 
TDLN cells 
DC cultures were sampled at day 3, 5, and day 7 
respectively and stained with FITC conjugated 
anti-CD11c, anti-I-Ab, and anti-CD86 (all from Dia-
clone, Besancon, France). After activation, TDLN cells 
were permeablized and stained with FITC conjugated 
anti-IFN-γ or PE conjugated anti-IL-10 (both from 
Diaclone). Isotype-matching controls were used. 
FACS analysis was performed using a FACScan flow 
microfluorometer (Coulter, Fullerton, CA). 
7. Induction of TDLN  
To induce TDLN, 2×106 irradiated (25Gy) pa-
rental B16 cells or SEA gene-modified B16 cells plus 
20 μl BCG (Sigma) in 0.1 ml PBS was inoculated sub-
cutaneously (s.c) into the lower flanks of the B6 mice. 
The draining inguinal lymph nodes were collected 10 
days later, and were designated as wt TDLN and SEA 
TDLN respectively.   
8. Preparation of tumor lysate 
B16 cells were suspended in CM (1×108/ml) 
and subjected to three times of rapid freeze-thaw ex-
posures in liquid N2 and water bath, then spun at 12, 
000rpm for 20min to remove cellular debris. The su-
pernatant was saved and kept at -20oC for future use. 
Wild-type B16 tumor lysate was used in all of the ex-
periments involving DC stimulation of either wt 
TDLN or SEA TDLN during the culture of cells.   
9. Stimulation of TDLN T cells in vitro  
Multiple inguinal TDLN were pooled from 
groups of mice and were processed using mechanical 
dissociation for lymphoid cell suspension. T cells 
were purified using a nylon wool column. Purified T 
cells suspended in CM were then stimulated in 
96-well culture plate or in culture flask under the fol-
lowing conditions: (1) No stimulation (medium only); 
(2) Anti-CD3 (1 μg/ml) + anti-CD28 (1 μg/ml) + IL-2 
(1000IU/ml) (all from Diaclone); (3) Anti-CD3 (1 
μg/ml) + anti-CD28 (1 μg/ml) + IL-2 (1000IU/ml) + 
DC + tumor lysate. For each 1×105 T cells, 2×104 
DCs were used along with tumor lysates equivalent 
to 1×105 tumor cells. Stimulation lasted for 72 hours 
at 37oC with 5% CO2.  
10. Proliferation of TDLN T cells in vitro  
  Purified TDLN T cells were suspended at 5×
106/ml in CM. 100μl of cell suspension was added to 
each well of a 96-well culture plate. The experiment 
was preformed in triplicate. Stimuli were added as 
described above at 100 μl/well. The cells were incu-
bated at 37oC with 5% CO2 for 48 hours. 100μl super-
natant was removed from each well and 10μl MTT 
(Sigma, stock 5mg/ml) was added per well. Cells 
were cultured for another 4 hours before the addition 
of 100μl 10% SDS and 0.01mol LHC to each well. Cell 
culture continued overnight. OD values were then 
measured at wave length 570nm. 
11. Adoptive Immunotherapy 
Pulmonary metastases were induced by tail vein 
injection of 1 x 106 of B16 cells in 0.2 ml PBS in B6 
mice. Three days after tumor inoculation, the tu-
mor-bearing mice were treated with secondarily ac-
tivated TDLN cells through tail vein injection (2 x 106 
cells/mouse). Approximately 10 days after T cell 
transfer, all mice were randomized and sacrificed, 
and lungs were harvested for enumeration of pul-
monary metastatic nodules.   
12. CTL assay 
TDLN T cells were suspended at 1×106/ml in 
CM and were stimulated as described above. Stimu-
lated T cells were resuspanded at 4×106/ml and 
mixed with 3H-TdR (Amersham, Little Chalfont, 
U.K.)-labeled B16 cells at 40: 1, 20: 1, 10: 1 in a 
U-bottom 96-well plate. The volume was 200 μl/well. 
After culture at 37 oC with 5% CO2 for 18 hours, cpm 
was measured by 3H-counter (Backman, Fullerton, 
CA) and killing (%) was calculated.   
13. Statistical Analysis 
For comparison of tumor treatment in adoptive 
immunotherapy, Wilcoxon test was performed. Stu-
dents t-test was used to analyze cell proliferation and 
cytokine release. Statistical analysis was performed 
using SPSS software. Statistical significance was 
achieved when p<0.05. 
Results 
1. Construction of recombinant pcDNA3.1 
(+)/SEA and the transfection of B16 tumor cells  
We constructed a eukaryotic expression vector 
pcDNA3.1-SEA and transfected it into the B16 murine 
melanoma tumor cells by means of lipo-
some-mediated transfection. 
The SEA gene was amplified by PCR using the 
plasmid pGEM-Teasy-SEA (T/SEA) as a template. 
The PCR product was digested with Nhe I and EcoR I Int. J. Biol. Sci. 2009, 5 
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and ligated with similarly digested pcDNA3.1 
(+) using T4 ligase (Fig.1A). The recombinant 
pcDNA3.1 (+)/SEA was analyzed by restriction 
enzyme digestion at 37oC for 1 hour. The prod-
ucts were revealed on a 1.5% electrophoresis 
agarose gel (Fig.1B). It shows that enzyme di-
gestion using NheI and EcoRI resulted in a band 
of approximately 770bp, consistent with the es-
timated size of the SEA gene. In addition, the 
correctly constructed plasmids were confirmed 
by DNA sequencing (data not shown). B16 cells 
were transfected with 10 μg of the recombinant 
plasmid by Lipofectamine 2000. The stably 
transfected B16 cells were selected with G418 to 
obtain G418-resistant clones. Total RNA was 
isolated from the transfected cells and the cDNA 
was synthesized. The cDNA was then PCR am-
plified and the products were shown by DNA 
agarose gel electrophresis (Fig 1C). The bands at 
approximately 770bp represent the amplified 
SEA gene from three clones of SEA-transfected 
B16 tumor cells, thus confirming the successful 
gene transfer.   
 
 
 
 
 
Figure 1: A: Scheme for construction of recombinant 
expression vector pcDNA3.1 (+)/SEA. B: Restriction en-
zyme digestion of the recombinant expression vector 
pcDNA3.1-SEA. 1. λDNA/HindIII ladder; 2. 
pcDNA3.1-SEA/NheI + EcoRI; 3. pcDNA3.1-SEA/EcoRI; M: 
DL2000 marker. C: Transfected SEA fragment confirmed 
by RT-PCR product on agarose gel electrophoresis. Lanes 
1-3: Three clones of SEA-B16 cells; M: DNA marker 
(DL2000).  
DCs were used in this study during in vitro 
TDLN cell stimulation. To induce splenomegaly, mice 
were injected with cyclophosphamide. Eight days 
later, spleens were harvested. Splenocyte suspension 
was prepared and depleted of erythrocytes. The re-
sultant cells were suspended at 1×106 /ml in CM. 
Cells were cultured in a flask at 37oC with 5% CO2. 
Three days later, culture medium and non-adherent 
cells were removed and discarded. Adherent cells 
were then cultured with fresh CM containing 
GM-CSF (20 ng/ml) and IL-4 (10 ng/ml). Half of the 
culture medium was replaced by fresh medium every 
other day. Five days later, TNFα (1ng/ml) was 
added. After culture for 2 more days, cells were col-
lected for morphological observation under micro-
scope. The GM-CSF and IL-4-cultured cells observed 
under phase-contrast and electron microscopes 
demonstrated the typical characteristics of DC mor-Int. J. Biol. Sci. 2009, 5 
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phology (Fig.2). Meanwhile, the phenotype of the 
cultured DC cells was analyzed by FACS staining. 
Cell cultures were sampled at day 3, 5, and day 7 
without TNFα or day 7 with TNFα respectively and 
stained with FITC-conjugated anti-CD11c, anti-I-Ab, 
and anti-CD86. FACS analysis indicated that the ex-
pression of CD11c and MHC II (I-Ab) molecules 
showed an ascending tendency 
with the time of cell culture (data 
not shown). On day 7, the CD11c, 
I-Ab,  o r  C D 8 6  p o s i t i v e  c e l l s  w e r e  
34%, 25%, and 75% respectively. 
Importantly, with the addition of 
TNFα, the expression of these 
markers was enhanced to 78%, 
58%, and 81% respectively, signi-
fying the noteworthy role of TNFα 
in DC maturation. 
 
 
Figure 2: Morphological observation 
of DCs under phase contrast micro-
scope, scanning electron microscope, 
and transmission electron microscope 
after cell culture for 7 days. 
 
2. Significantly enhanced in vi-
tro proliferation of SEA TDLN cells induced by 
anti-CD3, anti-CD28 and IL-2 plus DC and tumor 
antigen 
The inguinal lymph nodes draining the parental 
B16 or SEA-B16 tumor vaccines were collected and 
were designated as wt TDLN or SEA TDLN respec-
tively. Purified TDLN T cells were activated with T 
cell specific polyclonal antibody anti-CD3, anti-CD28 
mAbs and maintained in culture with exogenous T 
cell growth factor IL-2 with or without DC plus tu-
mor lysate. MTT analysis was then performed to 
measure cell proliferation. As shown in Figure 3, 
group A demonstrated the highest proliferation index 
(63%), which is significantly higher (p<0.01) than any 
other groups. The proliferation index of group B 
(41%) was much lower, but it was significantly higher 
than control (group C, 12%). These data indicate that 
anti-CD3, anti-CD28, and IL-2 simulated significant 
proliferation of SEA TDLN T cells, which could be 
radically augmented by the simultaneous use of DC 
and tumor lysates. It is worthy noting, when com-
paring wt TDLN with SEA TDLN, that SEA TDLN 
c e l l s  p r o l i f e r a t e d  m o r e  v i g o r o u s l y  t h a n  w t  T D L N  
cells in response to the similar activation conditions. 
For instance, the proliferation indexes of wt TDLN 
cells after stimulation with anti-CD3, anti-CD28, IL-2 
were 38% (group D) and 5% (group E) respectively in 
the presence and absence of DC plus tumor lysate. 
These data thus revealed more active proliferation of 
antibody-activated SEA TDLN cells (group B) com-
pared with antibody-activated wt TDLN cells (group 
E), and this antibody-activated SEA TDLN cell pro-
liferation can be further increased with DC plus tu-
mor antigen (group A). Collectively, these data sug-
gest the critical role of enforced expression of SEA to 
enhance the immunogenicity of the tumor vaccine 
during the in vivo sensitization of TDLN cells, and 
advocate the usefulness of antigen-presenting cells 
and tumor antigen during the in vitro activation and 
expansion of these TDLN cells.   
 
 
Figure 3: Proliferation of TDLN cells stimulated with 
different conditions. Multiple inguinal TDLNs were pooled 
from groups of mice and were processed for lymphoid cell Int. J. Biol. Sci. 2009, 5 
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suspension. T cells were purified using the nylon wool 
column. Purified T cells were stimulated under the following 
conditions: Group A, D:  Anti-CD3 + anti-CD28 + IL-2 plus 
DC and tumor lysates; Group B, E:  Anti-CD3 + anti-CD28 
+ IL-2; Group C, F: Un-stimulated (medium only). 100μl of 
cell suspension was added to each well of 96-well culture 
plate in triplicate. Stimuli described above were added at 
100μl/well. After culture for 48 hours, cell proliferation was 
measured with MTT analysis. P<0.01: A vs. B; A vs. C; A vs. 
D. B vs. E; C vs. F. D vs. E; D vs. F. 
 
 
 
 
 
3. Therapeutic efficacy of TDLN cells post anti-
body, IL-2 and DC stimulation 
 To test the therapeutic efficacy of T cells gener-
ated from the lymph node draining the 
SEA-expressing tumor and secondarily activated with 
DC, we performed adoptive transfer experiments 
with established tumors.   
  B6 mice bearing three-day wt B16 pulmonary 
metastases were treated with stimulated SEA TDLN 
or wt TDLN cells. These TDLN cells were stimulated 
in vitro using anti-CD3/anti-CD28/IL-2 with or 
without DC and tumor antigen. Therapeutic efficacy 
was compared with those using un-stimulated TDLN 
cells. In control mice that received no treatment, me-
tastatic nodules were more than 250 (data not shown) 
at the end of the experiments. As shown in Figure 4, 
unstimulated SEA TDLN and wt TDLN cells medi-
ated marginal tumor regression. The metastatic nod-
ules were around 200, and these T cells inhibited tu-
mor growth by 25% (group C), and 15% (group F) 
respectively, with SEA TDLN (group C) being more 
effective. However, anti-CD3/anti-CD28/IL-2- 
stimulated SEA TDLN and wt TDLN cells mediated 
significant tumor regression. The metastatic nodules 
were around 150, and these T cells inhibited tumor 
growth by 53% (group B), and 43% (group E) respec-
tively, again, with SEA TDLN (group B) being more 
effective. Importantly, the most potent antitumor ef-
fector cells were those generated from SEA TDLN 
and stimulated in vitro using 
anti-CD3/anti-CD28/IL-2 plus DC and tumor anti-
gen (group A). These cells inhibited tumor growth by 
almost 90%. The therapeutic efficacy by these cells 
was also significantly (p<0.01) higher than that medi-
a t e d  b y  s i m i l a r l y  s t i m u l a t e d  w t  T D L N  c e l l s  ( g r o u p  
D). Taken together, the therapeutic data confirm that 
the SEA-expressing B6 tumors are more immuno-
genic in inducing TDLN cells in vivo, and that the 
subsequent use of DC to present tumor antigen in 
vitro in concert with anti-CD3, anti-CD28 and IL-2 can 
generate more potent antitumor effectors from the 
TDLN cells.   
 
Figure 4: SEA TDLN cells activated with 
anti-CD3/anti-CD28/IL-2 plus DC and tumor antigen 
demonstrated the most potent therapeutic efficacy. In these 
adoptive transfer experiments, pulmonary metastases were 
induced by tail vein injection of 1 x 10
6 of wt B16 cells in 0.2 
ml PBS in B6 mice. Three days later, the tumor-bearing mice 
were treated with variously activated TDLN cells (2 x 10
6 
cells/mouse) by tail vein injection. Approximately 10 days 
after T cell transfer, all mice were randomized and sacri-
ficed, and lungs were harvested for enumeration of pul-
monary metastatic nodules. TDLN cells were activated with 
anti-CD3/anti-CD28/IL-2 plus DC and tumor antigen 
(Group A, D); anti-CD3/anti-CD28/IL-2 (Group B, E), or 
un-stimulated (Group C, F).  P<0.01: A vs. B; A vs. C; A vs. 
D; B vs. E; C vs. F; D vs. E; D vs. F. 
 
4. Augmented therapeutic efficacy of antibody 
plus DC-activated SEA TDLN cells correlates 
with higher CTL activity and increased IFNγ se-
cretion  
To appreciate the mechanisms which may be 
involved in the augmented therapeutic efficacy me-
diated by antibody plus DC-activated SEA TDLN 
cells, we examined the immune function of these 
cells. Killing of wt B16 tumor cells by wt TDLN or 
SEA TDLN T cells stimulated under various condi-
tions were compared. As illustrated in Figure 5, for 
SEA TDLN, stimulation with anti-CD3, anti-CD28, 
and IL-2 plus DC and tumor antigen resulted in a 
most potent cell killing (group A), followed by 
stimulation with anti-CD3, anti-CD28 and IL-2 (group 
B). Wt TDLN also showed superior cell killing when Int. J. Biol. Sci. 2009, 5 
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anti-CD3, anti-CD28, IL-2 were used together with 
DC plus tumor lysate (group D) compared with that 
when anti-CD3, anti-CD28 and IL-2 were used with-
out DC (group E). These data show that DC and tu-
mor antigen used in vitro boosts CTL activity in 
TDLN cells induced by antibody and IL-2. On the 
other hand, SEA TDLN revealed higher tumor cell 
killing than wt TDLN cells stimulated under the same 
conditions. For example, the cell killing of SEA TDLN 
cells after stimulation with antibody and IL-2 in the 
p r e s e n c e  o f  D C  p l u s  t u m o r  l y s a t e  ( g r o u p  A )  w a s  
h i g h e r  t h a n  t h a t  o f  w t  T D L N  c e l l s  s i m i l a r l y  s t i m u -
lated (group D). Also, antibody and IL-2-induced cell 
killing of SEA TDLN cells in the absence of DC and 
tumor lysate (group B) was higher than that of wt 
TDLN cells similarly stimulated (group E). SEA 
TDLN cells are more cytolytic to tumors after anti-
body and tumor antigen stimulation compared with 
wt TDLN cells. These data support the notion that 
enhanced CTL activity may contribute to the im-
proved therapeutic efficacy of antibody and 
DC-stimulated SEA TDLN cells. 
 
Figure 5: In vitro CTL activity of TDLN cells stimulated 
with different conditions. SEA TDLN and wt TDLN T cells 
were stimulated using anti-CD3 + anti-CD28 + IL-2 with 
(group A, D) or without (group B, E) DC plus tumor lysate, 
or left un-stimulated (group C, F), as in Figure 3. Stimulated 
T cells were washed, re-suspended at 4×10
6/ml and mixed 
with 
3H-TdR-labeled B16 cells at 40: 1, 20: 1, and 10: 1 in 
U-bottom 96-well plate. After culture at 37
oC with 5% CO2 
for 18 hours, cpm was measured and the killing index was 
calculated.  
 
Another critical machinery involved in tumor 
rejection is the elaboration of cytokines by the effector 
cells [31, 32]. In parallel with the CTL analysis, we 
examined the cytokine secretion of SEA TDLN cells. 
Comparison was made between the wt TDLN and 
SEA TDLN cells stimulated using anti-CD3 + 
anti-CD28 + IL-2 with or without the use of DC and 
tumor lysate. Cytokine secretion was examined at the 
end of cell stimulation by intracellular staining. IFNγ 
and IL-10 production are shown in Figure 6. For SEA 
TDLN, the percentage of IFNγ secreting cells was ap-
proximately 70% (group B) and 90% (group A) re-
spectively after T cell stimulation using anti-CD3 + 
anti-CD28 + IL-2 without or with DC and tumor an-
tigen. Similarly, the use of DC increased the number 
of IFNγ secreting wt TDLN T cells from 40% (group 
E) to 80% (group D) after anti-CD3 + anti-CD28 + IL-2 
stimulation. In contrast, when IL-10 was examined, 
an opposed effect of DC was found. In SEA TDLN, 
the percentage of IL-10-secreting cells was 8% (group 
B) and 5% (group A) respectively after T cells were 
stimulated using anti-CD3 + anti-CD28 + IL-2 with-
out or with DC plus tumor antigen. Similarly, the use 
of DC decreased the number of IL-10-secreting wt 
TDLN T cells from 13% (group E) to 4% (group D) 
with anti-CD3+ anti-CD28 + IL-2 stimulation. In line 
with the proliferation and CTL analyses, these data 
suggest that DC, when used in vitro to present tumor 
antigen in concert with anti-CD3/anti-CD28/IL-2, 
could modulate the immune function of TDLN cells, 
namely by enhancing the production of type 1 cyto-
kine, e.g. IFNγ and simultaneously inhabiting the se-
cretion of type 2 cytokine, e.g. IL-10.   
 
Figure 6: IFNγ and IL-10 expression on activated TDLN 
cells. SEA TDLN and wt TDLN T cells were stimulated 
using anti-CD3 + anti-CD28 + IL-2 with (groups A, D) or 
without (groups B, E) DC plus tumor lysate, or left 
un-stimulated (groups C, F), as in Figure 3. After activation 
for 48 hours, TDLN T cells were permeablized and stained 
with FITC-conjugated anti-IFN-γ or PE-conjugated 
anti-IL-10. FACS analysis was then performed. Int. J. Biol. Sci. 2009, 5 
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Discussion 
We report in this study that immunization of 
mice with B16 tumors genetically engineered to ex-
press SEA induces the antitumor immune response of 
T cells in the lymph nodes draining the 
SEA-expressing tumor. Secondary activation of these 
TDLN cells with DC plus tumor antigen in the pres-
ence of anti-CD3/anti-CD28/IL-2 amplifies their an-
titumor activity. As a result, adoptive transfer of 
these T cells mediates more effective tumor regres-
sion in the mice bearing the wild type B16 tumor 
compared with activated wt TDLN cells. These data 
present evidence that in vivo sensitization of TDLN 
draining a tumor with modulated immunogenicity 
followed by in vitro stimulation with combined use of 
antigen-presenting cells and T cell activation anti-
bodies can profoundly alter the therapeutic efficacy 
of the TDLN cells. The sequential use of SEA-B16 
vaccine  in vivo and the use of anti-CD3/CD28 plus 
DC and tumor antigen in vitro to generator antitumor 
effector cells for adoptive immunotherapy represents 
a novel procedure described in this study.   
  Poorly immunogenic B16 melanoma cells have 
been genetically engineered to improve their immu-
nogenicity by forced expression of several immune 
modulator molecules [33-36]. We examined the ef-
fects of in vivo transfection of an allogeneic MHC class 
I gene (H-2Ks) into the B16 melanoma of H-2b origin 
[35], and the host immune response to B16 melanoma 
transduced to secrete granulocyte-macrophage col-
ony-stimulating factor (GM-CSF) [34]. Likewise, ge-
netic modification of human melanoma tumor cells 
has resulted in clinical benefit. Adoptive transfer of 
GM-CSF-secreting vaccine-primed lymph node cells 
resulted in a durable complete remission of metas-
tatic tumor in melanoma patients [37], although the 
clinical response was confined to a limited population 
of patients. In addition, gene transfer of a foreign 
MHC class I protein, HLA-B7, into HLA-B7-negative 
patients with stage IV melanoma stimulated local 
antitumor immune responses that facilitated the gen-
eration of effector cells for immunotherapy of cancer 
[38]. In addition, we evaluated the in vivo response to 
B16 melanoma genetically altered to secrete IL-2, IL-4 
and IFNγ. Secretion of IL-2 abrogated the tumori-
genicity of B16, while IFNγ and IL-4 partially reduced 
tumorigenicity. However, neither IL-2 nor IFNγ se-
cretion resulted in the induction of immune T cells in 
the TDLN. These studies demonstrated that reduced 
tumorigenicity did not correlate with increased im-
munogenicity [36]. In this study, we found that SEA 
expression conveyed super antigenicity to tumor 
cells, which evoked T cells in the draining lymph 
nodes to suppress tumor growth upon adoptive 
transfer. 
 SEA has been previously expressed on tumor 
cells to increase their immunogenicity and to serve as 
a target for T cells [20, 21, 39]. This was done either by 
modifying the tumor with transmembrane-anchored 
SEA (TM-SEA) using the protein transfer technique 
[20], or by antibody targeting using a recombinant 
protein of SEA and the Fab-fragment of a tu-
mor-reactive antibody [21, 39]. In this report, we 
modified B16 by SEA gene transfer. This strategy al-
tered the immunogenicity of the genetically modified 
tumor when used as vaccine, and induced more po-
tent tumor-reactive TDLN cells. This was demon-
strated by more vigorous cell proliferation, higher 
CTL activity, and significantly augmented therapeu-
tic efficacy of the SEA TDLN cells compared with 
similarly in vitro simulated TDLN cells draining the 
parental tumor.   
  It was shown that genetic modification of tu-
mors could be made more efficient in tumor immu-
notherapy by concomitant DC administration [11]. 
On the other hand, Ag-specific in vitro DC-driven 
proliferation and differentiation of T cells from 
HIV-1-infected patients were documented [40]. Anti-
gen specific T cells were also generated from periph-
eral blood [41] or from naive spleen-derived T cells 
[27] by in vitro stimulation with DC and the relevant 
antigen. DCs have also been used in vitro to generate 
human antitumor effectors. For example, cancer pa-
tients' memory T cells from bone marrow could be 
specifically activated to become cytotoxic effector 
cells by short-term culture with autologous DC 
pre-pulsed with tumor lysates [42]. Both human 
CD4+ and CD8+ renal cell carcinoma-reactive T cells 
were generated using a completely autologous sys-
tem of DCs presenting whole ultraviolet-irradiated 
apoptotic tumor cells [43]. The function of CD4 cells 
relevant to CD8 cells generated from TDLN has also 
been documented in the adoptive immunotherapy 
models [30, 44, 45]. In this report, we used DC and 
tumor antigen in vitro to stimulate TDLN cells iso-
lated from the hosts vaccinated with a genetically 
modified tumor, and the in vitro stimulation was 
performed in the presence of T cell specific antibod-
ies, anti-CD3 and anti-CD28 plus the T cell growth 
factor IL-2. The secondary stimulation in vitro with 
the use of DC amplifies the antitumor activity in-
duced by the genetically modified tumor as vaccine 
in vivo. Consequently, DC-stimulated SEA TDLN cells 
eliminated nearly 90% of the pulmonary metastasis in 
mice bearing established B16 melanoma micrometas-
tases. The sequential use of genetically modified tu-
mor as vaccine to induce TDLN followed by secon-Int. J. Biol. Sci. 2009, 5 
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dary stimulation using APCs and tumor antigen 
represents a unique combination method to generate 
tumor reactive T cells.   
We found in this study that addition of DC and 
tumor lysate to T cell culture with 
anti-CD3/anti-CD28/IL-2 increases the elaboration of 
IFNγ but diminishes the secretion of IL-10 by TDLN 
cells. This cytokine profile correlated with a superior 
therapeutic efficacy. Several groups, including our 
own, have reported previously that the cytokine pro-
file secreted by lymphoid cells correlates with the 
outcome of antitumor activity in cancer immuno-
therapy [8, 28, 29, 31]. In a tumor-reactive anti-
body-targeted immunotherapy using the SEA-mAb 
complex, IFNγ  was found to be suppressive to tu-
mor, while in contrast high level of IL-10 was dem-
onstrated to inhibit Fab-SEA tumor therapy, since the 
therapeutic efficacy was significantly higher in IL-10 
KO mice [39]. Moreover, incubation of T cells with 
autologous ovarian tumor cell lysate-pulsed DC 
stimulated proliferation of T cells and production of 
Th1 cytokines [46]. Collectively, these data support 
the efforts to promote the expression of type1 cyto-
kines in order to develop more effective immuno-
therapy strategies [7-8, 28]. In this regard, DC may 
play an important role even though the molecular 
mechanisms remain to be defined to further elucidate 
these observations.   
With the use of T cells generated from lymph 
nodes draining an SEA-expressing murine B16 mela-
noma and secondarily activated with DC plus B16 
tumor antigen in this study, significant remission of 
established solid tumors was achieved. It would be 
interesting to see what will happen when B16 tumor 
cells are inoculated into the mice that have been pre-
viously immunized with SEA-expressing B16 cells. 
Normal mice injected with SEA-B16 followed by in-
oculation of wt-B16 tumor cells to see if wt-B16 will 
grow or the growth will be retarded should allow us 
to test the protective immunity which may be in-
duced by SEA-B16 as a vaccine.   
 While the lung metastatic model has been used 
extensively in studies of adoptive transfer therapy 
including TDLN-related approaches as we described 
in this study, the use of subcutaneous (sc) tumor 
model [22, 23, 45] would provide additional data to 
support the use of SEA-B16 vaccine in vivo and 
anti-CD3/CD28 plus DC and tumor antigen in vitro to 
generator antitumor effector cells for adoptive im-
munotherapy. Nevertheless, the preclinical studies 
reported herein provide compelling evidence that 
genetic introduction of bacterial superantigen SEA 
into poorly immunogenic tumors appears to be a 
promising strategy for rendering tumors more im-
munogenic. SEA-modified tumor vaccine conferred 
the induction of more potent tumor-reactive T cells 
within the lymph nodes draining the vaccine. Subse-
quent in vitro stimulation of these lymph node cells 
using DC and tumor antigen amplifies the antitumor 
activity and results in more potent therapeutic effec-
tor T cells. These findings have shown the feasibility 
to combine the use of a genetically modified tumor 
vaccine with a secondary in vitro activation procedure 
involving antigen presenting cells in future clinical 
trials, and may lead to the development of novel 
protocols for cancer immunotherapy. 
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